Article
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Familial cancer - 1 Mar 2012
Pujol Pascal, Lasset Christine, Berthet Pascaline, Dugast Catherine, Delaloge Suzette, Fricker Jean-Pierre, Tennevet Isabelle, Chabbert-Buffet Nathalie, This Pascale, Baudry Karen, Lemonnier Jerome, Roca Lise, Mijonnet Sylvie, Gesta Paul, Chiesa Jean, Dreyfus Helene, Vennin Philippe, Delnatte Capucine, Bignon Yves Jean, Lortholary Alain, Prieur Fabienne, Gladieff Laurence, Lesur Anne, Clough Krishna B, Nogues Catherine, Martin Anne-Laure
Abstract excerpt
Women with germline BRCA1 or BRCA2 (BRCA1/2) mutations are considered as an extreme risk population for developing breast cancer. Prophylactic mastectomy provides a valid option to reduce such risk, impacting however, the quality of life. Medical prevention by aromatase inhibitor that has also recently shown to have preventive effect may thus be considered as an alternative. LIBER is an ongoing double-blind,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
